Assessment of a Femtosecond Laser to Perform Capsulorhexis During Cataract Surgery

Cataract Surgery Clinical Trial

Official title:

Assessment of a Hand-held Femtosecond Laser to Perform Anterior Capsulorhexis During Cataract Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05141370
• Other study ID #: 2021-A02331-40
• Status: Completed
• Phase: N/A
• Start date: February 3, 2022
• Est. completion date: April 3, 2023

Study information

• Verified date: September 2023
• Source: Ilasis Laser
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a Pre-market first-in-man clinical investigation to validate performance of a hand-held femtosecond laser named CATSYS.

Description:

Interventional, prospective, longitudinal (follow-up: 30 ± 10 days), single-arm, single center, open trial. The "first-in-man" character of this investigation relies on the ergonomics of CATSYS (handpiece), and not on the laser technique, which is similar to other FLACS.

The purpose of the clinical investigation is to document the compliance of the investigational medical device with the general requirements of performance, safety and clinical benefit, in order to complete existing data and obtaining CE-mark for CATSYS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: April 3, 2023
• Est. primary completion date: April 3, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with cataract requiring surgery according to current guidelines;

• Eligible to lens removal by phacoemulsification and replacement by a prosthetic lens under local anesthesia;

• Who have been informed and gave informed consent to participate in the study.

Exclusion Criteria:

• Eye with an anterior chamber depth < 2.5 mm or > 3.8 mm;

• Corneal disease or pathology that precludes applanation of the cornea or transmission of laser wavelength or distortion of laser light;

• Eye with a poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally;

• Patient with residual, recurrent, active ocular or eyelid disease, including any corneal abnormality (for example, recurrent corneal erosion, severe basement membrane disease) in either eye;

• History of steroid-responsive rise in IOP, glaucoma, or preoperative IOP>21 mm Hg in either eye;

• Lens/zonular instability such as, but not restricted to, Marfan's Syndrome, pseudoexfoliation syndrome, etc;

• Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye;

• Any recent penetrating incision of the eyeball;

• Tilt of lens > 7;

• Presence of any obstacle that may interfere with the stabilization of the device on the limbus: pterygium, limbic tumor, etc;

• Pregnant or lactating woman;

• Patient with any contra-indication to neosynephrine, tropicamide and oxybuprocaïne;

• Patient presenting any contraindications to cataract surgery under local anesthesia (ex: allergy to anesthetic drops; neurodegenerative disease; schizophrenia; severe anxiety; etc.);

• Patient who participates to another clinical trial (except observational studies), or in the exclusion period of another clinical trial;

• Patient under guardianship, trusteeship or deprived of liberty;

• Patient not affiliated to the French social security system;

• Patient unable to participate in the study for psychiatric, cognitive or linguistic reasons.

Related Conditions & MeSH terms

• Cataract
• Cataract Surgery

Intervention

Device:
• cataract surgery with CATSYS
patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS

Locations

Country	Name	City	State
France	Institut Opthalmologique Sourdille Atlantique	Saint-Herblain

Sponsors (1)

Lead Sponsor	Collaborator
Ilasis Laser

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Continuity of the capsulorhexis (success / failure)	Success achieved if: the anterior capsule is completely cut (rhexis is free floating or easy to remove); AND there are no peripheric tears that can generate the rupture of the capsule at the end of rhexis removal.	During surgery
Secondary	Adverse device effects	Collection of adverse device effects by the investigator on the retina, on the cornea, on the posterior capsula and other adverse device events	3 to 5 days after surgery
Secondary	Adverse events	Collection by the investigator of other adverse events	3 to 5 days post-surgery;
Secondary	Ocular adverse events	Collection by the investigator of ocular adverse events	30 ± 10 days post-surgery.